Following a flurry of activity in early 2025, the IPO scene has cooled in the wake of President Trump’s economic tremors.

Mosanna Therapeutics has secured $80m in a Series A funding round for advancing new nighttime nasal spray for obstructive ...

The 17 sitting members of the Advisory Committee on Immunization Practices (ACIP) will be replaced by new members chosen by ...

The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.

YolTech has received FDA approval for its investigational new drug (IND) application for YOLT-101 to treat HeFH.

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

In this article, GlobalData examines key reimbursement trends that reflect the current delays to patient access across the ...

Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.

During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.

A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) ...